Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1.

Cardaci S, Rizza S, Filomeni G, Bernardini R, Bertocchi F, Mattei M, Paci M, Rotilio G, Ciriolo MR.

Cancer Res. 2012 Sep 1;72(17):4526-36. doi: 10.1158/0008-5472.CAN-12-1741. Epub 2012 Jul 6.

2.
3.

Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.

Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF.

Anticancer Res. 2013 Jan;33(1):13-20. Review.

PMID:
23267123
4.

Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.

Queirós O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, Casal M.

J Bioenerg Biomembr. 2012 Feb;44(1):141-53. doi: 10.1007/s10863-012-9418-3. Epub 2012 Feb 17.

PMID:
22350013
5.

Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity.

Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y, You M.

Cancer Prev Res (Phila). 2012 May;5(5):717-25. doi: 10.1158/1940-6207.CAPR-11-0338. Epub 2012 Mar 8.

6.

Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.

Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, Ganapathy V.

Cancer. 2009 Oct 15;115(20):4655-66. doi: 10.1002/cncr.24532.

7.

L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.

Tardito S, Chiu M, Uggeri J, Zerbini A, Da Ros F, Dall'Asta V, Missale G, Bussolati O.

Curr Cancer Drug Targets. 2011 Oct;11(8):929-43.

PMID:
21834755
8.

D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects.

El Sayed SM, El-Magd RM, Shishido Y, Yorita K, Chung SP, Tran DH, Sakai T, Watanabe H, Kagami S, Fukui K.

J Bioenerg Biomembr. 2012 Oct;44(5):513-23. doi: 10.1007/s10863-012-9455-y. Epub 2012 Jul 17.

PMID:
22802136
9.

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Anticancer Drugs. 2014 Jul;25(6):673-82. doi: 10.1097/CAD.0000000000000094.

PMID:
24557015
10.

EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate.

Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, Lizak M, Merkle H, Ardenkjaer-Larsen JH, Choudhuri R, Devasahayam N, Subramanian S, Koretsky AP, Mitchell JB, Krishna MC.

Magn Reson Med. 2013 May;69(5):1443-50. doi: 10.1002/mrm.24355. Epub 2012 Jun 12.

11.

Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells.

Davidescu M, Sciaccaluga M, Macchioni L, Angelini R, Lopalco P, Rambotti MG, Roberti R, Corcelli A, Castigli E, Corazzi L.

J Bioenerg Biomembr. 2012 Feb;44(1):51-60. doi: 10.1007/s10863-012-9411-x. Epub 2012 Feb 9.

PMID:
22318357
12.

MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.

Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, Hutchins AW, Gultekin Y, Peterson TR, Carette JE, Brummelkamp TR, Clish CB, Sabatini DM.

Nat Genet. 2013 Jan;45(1):104-8. doi: 10.1038/ng.2471. Epub 2012 Dec 2.

13.

3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.

Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Geschwind JF.

Curr Pharm Biotechnol. 2010 Aug;11(5):510-7. Review.

PMID:
20420565
14.

The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH.

Azevedo-Silva J, Queirós O, Ribeiro A, Baltazar F, Young KH, Pedersen PL, Preto A, Casal M.

Biochem J. 2015 Apr 15;467(2):247-58. doi: 10.1042/BJ20140921.

PMID:
25641640
15.

Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition.

Diers AR, Broniowska KA, Chang CF, Hogg N.

Biochem J. 2012 Jun 15;444(3):561-71. doi: 10.1042/BJ20120294.

PMID:
22458763
16.

Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent.

Dell'Antone P.

Med Chem. 2009 Nov;5(6):491-6.

PMID:
19534685
17.

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae.

Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ułaszewski S.

J Bioenerg Biomembr. 2012 Feb;44(1):155-61. doi: 10.1007/s10863-012-9421-8. Epub 2012 Feb 23.

PMID:
22359102
18.

Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.

Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P.

Cancer Res. 2012 Oct 1;72(19):5130-40. doi: 10.1158/0008-5472.CAN-12-1949. Epub 2012 Jul 31.

19.

Oxidative stress and reduced glutamine synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis.

Castegna A, Palmieri L, Spera I, Porcelli V, Palmieri F, Fabis-Pedrini MJ, Kean RB, Barkhouse DA, Curtis MT, Hooper DC.

Neuroscience. 2011 Jun 30;185:97-105. doi: 10.1016/j.neuroscience.2011.04.041. Epub 2011 Apr 24.

PMID:
21536110
20.

Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase.

Rodrigues-Ferreira C, da Silva AP, Galina A.

J Bioenerg Biomembr. 2012 Feb;44(1):39-49. doi: 10.1007/s10863-012-9413-8. Epub 2012 Feb 10.

PMID:
22322891
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk